These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35859633)

  • 21. Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis.
    Hu Y; Wang J; Rao J; Xu X; Cheng Y; Yan L; Wu Y; Wu N; Wu X
    Int Immunopharmacol; 2020 Mar; 80():106130. PubMed ID: 31978800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
    Kupersmith MJ
    J Neurol; 2009 Aug; 256(8):1314-20. PubMed ID: 19377863
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prediction of generalization of ocular myasthenia gravis under immunosuppressive therapy in Northwest China.
    Ding J; Zhao S; Ren K; Dang D; Li H; Wu F; Zhang M; Li Z; Guo J
    BMC Neurol; 2020 Jun; 20(1):238. PubMed ID: 32527235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognosis of Ocular Myasthenia Gravis in an Argentinian Population.
    Aguirre F; Villa AM
    Eur Neurol; 2018; 79(3-4):113-117. PubMed ID: 29428956
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autoimmunity in ocular and generalised myasthenia gravis.
    Garlepp MJ; Dawkins RL; Christiansen FT; Lawton J; Luciani G; McLeod J; Bradley J; Genkins G; Teng CS
    J Neuroimmunol; 1981 Sep; 1(3):325-32. PubMed ID: 7334085
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
    Isshiki Y; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for conversion to generalization in ocular myasthenia gravis.
    Witthayaweerasak J; Rattanalert N; Aui-Aree N
    Medicine (Baltimore); 2021 May; 100(19):e25899. PubMed ID: 34106649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric Autoimmune Ocular Myasthenia Gravis: Evaluation of Presentation and Treatment Outcomes in a Large Cohort.
    Fisher KS; Gill J; Todd HF; Yang MB; Lopez MA; Abid F; Lotze T; Shah VS
    Pediatr Neurol; 2021 May; 118():12-19. PubMed ID: 33684630
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comparison of electrodiagnostic tests in ocular myasthenia gravis.
    Katzberg HD; Bril V
    J Clin Neuromuscul Dis; 2005 Mar; 6(3):109-13. PubMed ID: 19078758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ocular Myasthenia Gravis: A Current Overview.
    Behbehani R
    Eye Brain; 2023; 15():1-13. PubMed ID: 36778719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single fiber electromyography in the diagnosis of ocular myasthenia gravis: report of 90 cases.
    Cui LY; Guan YZ; Wang H; Tang XF
    Chin Med J (Engl); 2004 Jun; 117(6):848-51. PubMed ID: 15198885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular myasthenia gravis - How effective is low dose prednisone long term?
    Verma R; Wolfe GI; Kupersmith MJ
    J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular manifestation and generalization after ocular onset in ocular myasthenia gravis: A 5-year analysis.
    Kemchoknatee P; Arepagorn A; Srisombut T
    Asian Pac J Allergy Immunol; 2021 Oct; ():. PubMed ID: 34717528
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy for ocular myasthenia gravis: an observational study in Japan.
    Narita T; Nakane S; Nagaishi A; Minami N; Niino M; Kawaguchi N; Murai H; Kira JI; Shimizu J; Iwasa K; Yoshikawa H; Hatanaka Y; Sonoo M; Shimizu Y; Matsuo H
    Ther Adv Neurol Disord; 2023; 16():17562864231163819. PubMed ID: 37051222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential Gut Microbiota and Fecal Metabolites Related With the Clinical Subtypes of Myasthenia Gravis.
    Tan X; Huang Y; Chai T; Zhao X; Li Y; Wu J; Zhang H; Duan J; Liang W; Yin B; Cheng K; Yu G; Zheng P; Xie P
    Front Microbiol; 2020; 11():564579. PubMed ID: 33013794
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of immune molecules CD25 and CXCL13 correlated with clinical severity of myasthenia gravis.
    Zhang M; Guo J; Li H; Zhou Y; Tian F; Gong L; Wang X; Li Z; Zhang W
    J Mol Neurosci; 2013 Jun; 50(2):317-23. PubMed ID: 23397576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review.
    Wilson L; Davis H
    Br Ir Orthopt J; 2023; 19(1):108-119. PubMed ID: 38046270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognosis of thymectomy in treatment of ocular myasthenia gravis and relevant influencing factors].
    Deng Y; Zhang X
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(27):1922-5. PubMed ID: 19953918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic nomogram for predicting generalized conversion in adult-onset ocular myasthenia gravis.
    Bi Z; Cao Y; Gui M; Lin J; Zhang Q; Li Y; Ji S; Bu B
    Neurol Sci; 2023 Apr; 44(4):1383-1391. PubMed ID: 36469201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.